LIGHT AT THE END OF THE TUNNEL?
ASTRAZENECA-OXFORD
A chimpanzee adenovirus-vectored vaccine (ChAdOx1) developed at Oxford’s Jenner Institute. Dosage could be 1.5
STATUS
Phase 3 trials on over 23,000 volunteers likely to be completed on December 22; interim results published. Twenty million doses already produced by the Serum Institute of India, which has applied to the DGCI for emergency use authorisation
EFFICACY AND SAFETY
Phase 1 and 2 trials on 1,077 adults showed a robust immune response. Phase 3 interim analysis of
